Abstract
The discovery of the natural product nodulisporic acid A (NsA A) and its potent, systemic insecticidal activity at Merck Research Laboratories in 1992 stimulated intense scientific scrutiny. Interest in this new class of indole diterpenes led to extensive delineation of its properties, both chemical and biological. Synthetic modification of NsA A served to identify its pharmacologically permissive and nonpermissive regions, produced semisynthetic derivatives with enhanced adulticidal flea efficacy (both in vitro and in vivo), and provided useful tools to support biological studies. Early observations in rodent models showed a wide therapeutic index for NsA A and detailed mechanism of action investigations demonstrated that it selectively modulated an invertebrate specific glutamate-gated ion channel for which no mammalian homolog exists. Consistent with these mechanistic conclusions, dogs treated orally with either NsA A or closely related amide analogs (15 mg / kg dosages) showed no apparent toxicity, and measurement of systemic flea efficacy in these animals demonstrated that prolonged antiparasitic activity was attained, up to 14 days subsequent to treatment with a single p.o. dose for fleas or up to 4 weeks for ticks. The extended flea efficacy was correlated to both the in vivo pharmacokinetic profile of a given analog and its intrinsic in vitro potency against fleas. In addition, studies directed towards the total synthesis of NsA A have been reported.
Keywords: nodulisporic acid, nsaa, indole diterpene, insecticidal, ivermectin
Current Topics in Medicinal Chemistry
Title: Nodulisporic Acid: Its Chemistry and Biology
Volume: 2 Issue: 7
Author(s): Peter T. Meinke, McHardy M. Smith and Wesley L. Shoop
Affiliation:
Keywords: nodulisporic acid, nsaa, indole diterpene, insecticidal, ivermectin
Abstract: The discovery of the natural product nodulisporic acid A (NsA A) and its potent, systemic insecticidal activity at Merck Research Laboratories in 1992 stimulated intense scientific scrutiny. Interest in this new class of indole diterpenes led to extensive delineation of its properties, both chemical and biological. Synthetic modification of NsA A served to identify its pharmacologically permissive and nonpermissive regions, produced semisynthetic derivatives with enhanced adulticidal flea efficacy (both in vitro and in vivo), and provided useful tools to support biological studies. Early observations in rodent models showed a wide therapeutic index for NsA A and detailed mechanism of action investigations demonstrated that it selectively modulated an invertebrate specific glutamate-gated ion channel for which no mammalian homolog exists. Consistent with these mechanistic conclusions, dogs treated orally with either NsA A or closely related amide analogs (15 mg / kg dosages) showed no apparent toxicity, and measurement of systemic flea efficacy in these animals demonstrated that prolonged antiparasitic activity was attained, up to 14 days subsequent to treatment with a single p.o. dose for fleas or up to 4 weeks for ticks. The extended flea efficacy was correlated to both the in vivo pharmacokinetic profile of a given analog and its intrinsic in vitro potency against fleas. In addition, studies directed towards the total synthesis of NsA A have been reported.
Export Options
About this article
Cite this article as:
Meinke T. Peter, Smith M. McHardy and Shoop L. Wesley, Nodulisporic Acid: Its Chemistry and Biology, Current Topics in Medicinal Chemistry 2002; 2 (7) . https://dx.doi.org/10.2174/1568026023393714
DOI https://dx.doi.org/10.2174/1568026023393714 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chronic Kidney Disease
The scope of the special thematic issue includes but not limited to the mechanism of chronic kidney disease (CKD), the treatment of renal fibrosis and early diagnosis of CKD and so on. We also welcome manuscripts from other scientific research area with respect to internal medicine. Cell death has been ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Privileged Scaffolds Targeting Bromodomain-containing Protein 4
Current Topics in Medicinal Chemistry Peptides and their Metal Complexes in Neurodegenerative Diseases: from Structural Studies to Nanomedicine Prospects
Current Medicinal Chemistry Development of Bilayer Tablet Containing Saxagliptin Immediate Release and Metformin Sustained Release Using Quality by Design Approach
Current Drug Therapy Treating Asthma as a Neuroelectrical Disorder
Inflammation & Allergy - Drug Targets (Discontinued) Rational Drug Design Approach of Receptor Tyrosine Kinase Type III Inhibitors
Current Medicinal Chemistry Dietary Polyphenols for Treatment of Alzheimer’s Disease– Future Research and Development
Current Pharmaceutical Biotechnology Molecule of the Month
Current Topics in Medicinal Chemistry Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews The Role of Adenosine in the Regulation of Sleep
Current Topics in Medicinal Chemistry Gene Therapy: The Role of Cytoskeleton in Gene Transfer Studies Based on Biology and Mathematics
Current Gene Therapy Angiogenesis Inhibitors: Current & Future Directions
Current Pharmaceutical Design Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Encapsulation of Imatinib in Targeted KIT-5 Nanoparticles for Reducing its Cardiotoxicity and Hepatotoxicity
Anti-Cancer Agents in Medicinal Chemistry Role of Mitochondrial Translocator Protein (18 kDa) on Mitochondrial- Related Cell Death Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Nano - Based Therapeutic Strategies in Management of Rheumatoid Arthritis
Recent Patents on Nanotechnology C. elegans as a Genetic Model System to Identify Parkinson's Disease- Associated Therapeutic Targets
CNS & Neurological Disorders - Drug Targets Soft Computing Techniques for the Protein Folding Problem on High Performance Computing Architectures
Current Drug Targets Role of Monocarboxylate Transporters in Drug Delivery to the Brain
Current Pharmaceutical Design Therapeutic Potential, Synthesis, Patent Evaluation and SAR Studies of Thieno[3,2-d]pyrimidine Derivatives: Recent Updates
Current Drug Targets Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets